Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopicdermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...
Some results have been hidden because they may be inaccessible to you